Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Pramlintide is a non-amyloidogenic analog of the antidiabetic peptide hormone amylin (Item Nos. 24274 | 24275) that contains proline residues substituted at positions 25, 28, and 29.1 It stimulates cAMP production in HEK293 cells expressing human amylin receptor 1a (AMY1a), AMY2a, and AMY3a (EC50s = 0.35, 22.9, and 0.89 nM, respectively).2 Pramlintide inhibits human islet amyloid polypeptide fibrilization in a concentration-dependent manner.3 In vivo, pramlintide (200 pg/kg) reduces brain levels of amyloid-β (1-40) (Aβ40; Item No. 21617) and increases spontaneous alternation in the Y-maze in the Tg2576 transgenic mouse model of Alzheimer's disease.4
WARNING This product is not for human or veterinary use.
1. Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility. Biochemistry 53(37), 5876-5584 (2014).
2. Activity of pramlintide, rat and human amylin but not Aβ1-
3. Analysis of the ability of pramlintide to inhibit amyloid formation by human islet amyloid polypeptide reveals a balance between optimal recognition and reduced amyloidogenicity. Biochemistry 54(44), 6704-6711 (2015).
4. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer’s disease. Mol. Psychiatry 20(2), 252-262 (2015).